Results 81 to 90 of about 34,139,948 (244)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

, 2015
Tara Gurung,1 Deepson S Shyangdan,1 Joseph Paul O’Hare,2 Norman Waugh1 1Warwick Evidence, 2Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK Background: Dulaglutide is a new, long-acting glucagon-
Shyangdan DS, O’Hare JP, Gurung T, Waugh N   +3 more
core  

A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use

The increasing prescription of glucagon-like peptide 1 (GLP-1) agonists presents a peri-operative challenge for anaesthetists. These drugs delay gastric emptying, potentially increasing pulmonary aspiration risk.
Endlich, Yasmin, Lin, D-Yin, Lam, Clayton YX   +2 more
core   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments. A systematic review and network meta-analysis

, 2015
Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments.
Zin Zin Htike (7682996), Melanie J. Davies (7155500), Francesco Zaccardi (285809), David R. Webb (200468), Kamlesh Khunti (171607)   +4 more
core   +5 more sources

Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report [PDF]

Malaysian Family Physician
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for weight management and glycaemic control. While generally well-tolerated, various adverse effects have been reported. Thyroid dysfunction, particularly hyperthyroidism,
Siti Nur Syakinah Md Sabudin, Lili Husniati Yaacob, Muhammad Rahmat Che Omar   +2 more
doaj   +1 more source

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies

Obesity is a chronic disease associated with multiple health risks. Multimodal treatments including lifestyle interventions, pharmacotherapies and bariatric surgery should be the standard of care for obesity management. Bariatric surgery remains the most
Kaivalya ABBURI (22136206), Dimitrios Papamargaritis (20339727), Eka MELSON (22136209), Alexander D MIRAS (22136212)   +3 more
core   +5 more sources

Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report

Journal of International Medical Research
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior have
Anisija Stojkovska, Polona Rus Prelog, Anja Kokalj Palandacic   +2 more
doaj   +1 more source

Nociceptin/orphanin FQ – NOP receptor system: novel genetic and pharmacological tools [PDF]

, 2012
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. In cells expressing the NOP receptor N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Molinari, Stefano
core  

Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro‐Eating Disorder Community on X (Formerly Twitter)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are complex conditions with medical and psychosocial implications. Social media (SM) exposure has been associated with increased body image concerns and maladaptive eating behaviors. Pro‐eating disorder (pro‐ED) communities exist across SM platforms and often perpetuate ED‐related identities and behaviors.
Daisy Sun, Tovah Yanover, Helena Katona, Jennifer Couturier   +3 more
wiley   +1 more source